-+ 0.00%
-+ 0.00%
-+ 0.00%

Capricor faces FDA advisory panel review of deramiocel in Duchenne muscular dystrophy

PUBT·07/27/2026 15:04:48
Listen to the news
Capricor faces FDA advisory panel review of deramiocel in Duchenne muscular dystrophy
  • Capricor will attend an FDA advisory committee meeting on July 29 to review its BLA for deramiocel in Duchenne muscular dystrophy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.